IP Library Granted Patent US 10,752,948
Granted Patent B2
US 10,752,948 · App. 16/238,874 · Granted Aug 25, 2020

Alpha-hemolysin variants

Inventors: Timothy Kellogg Craig (Campbell, CA); Cynthia Ann Cech (Newcastle, WA); Michael Dorwart (Mountain View, CA); Liv Elisabeth Jensen (Palo Alto, CA); Marshall Winston Porter (Santa Clara, CA); Christos Tzitzilonis (Mountain View, CA); Alexander Hyun-min Yang (Campbell, CA)
Assignee: Roche Sequencing Solutions, Inc.
C12Q1/6869C07K14/31
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,752,948
App. No.
16/238,874
Granted
Aug 25, 2020
Kind
B2
Abstract

Described herein are engineered alpha-hemolysin subunits having mutated oligomerization domains for assembling into heptameric nanopores in lipid bilayers.

Claims (27)

1. A hetero-oligomeric α-hemolysin (αHL) heptamer, comprising at least one preceding and at least one following subunit, each subunit comprising at least one αHL monomer and/or at least one polypeptide comprising concatenated αHL monomers,

wherein the at least one αHL monomer and/or the at least one polypeptide comprising concatenated αHL monomers comprises a mutation corresponding to H35L of SEQ ID NO:3; and

wherein the heptamer comprises exactly 7 αHL monomers, each αHL monomer comprising a first oligomerization domain and a second oligomerization domain, the first oligomerization domain of each αHL monomer being linked to the second oligomerization domain of a preceding αHL monomer and the second oligomerization domain of each αHL monomer being linked to the first oligomerization domain of a following αHL monomer.

2. The hetero-oligomeric αHL heptamer of claim 1 , wherein at least one αHL monomer further comprises a time-to-thread (TTT) substitution at a position corresponding to one or both of position 12 and position 17 of SEQ ID NO: 3.

3. An isolated polypeptide comprising one or more alpha-hemolysin monomers, wherein at least one of the alpha-hemolysin monomers comprises an amino acid sequence having at least 85% sequence identity to SEQ ID NO: 3 and an H35L substitution.

4. The isolated polypeptide of claim 3 , wherein one or more of the alpha-hemolysin monomers further comprise a time-to-thread (TTT) substitution at a position corresponding to position 12 and/or position 17 of SEQ ID NO: 3.

5. The isolated polypeptide of claim 4 , wherein the TTT substitution is selected from the group consisting of T12K, T12R, N17K, and N17R.

6. The isolated polypeptide of claim 3 having one alpha-hemolysin monomer.

7. The isolated polypeptide of claim 3 having at least two alpha-hemolysin monomers, wherein each monomer of the polypeptide is separated from each adjacent monomer in the polypeptide by a flexible linker.

8. The isolated polypeptide of claim 7 having from two to seven alpha-hemolysin monomers.

9. The isolated polypeptide of claim 3 , wherein at least one of the one or more alpha-hemolysin monomers further comprises an attachment component.

10. The isolated polypeptide of claim 9 , wherein the attachment component comprises a SpyTag or SpyCatcher peptide.

11. The isolated polypeptide of claim 9 , wherein the attachment component joins the alpha-hemolysin monomer to a DNA polymerase, an RNA polymerase, or a reverse transcriptase.

12. A heptameric pore complex comprising seven alpha-hemolysin monomers, wherein at least one of the alpha-hemolysin monomers comprises an amino acid sequence having at least 85% sequence identity to SEQ ID NO: 3 and an H35L substitution.

13. The heptameric pore complex of claim 12 , further comprising a polymerase linked to one of the alpha-hemolysin monomers.

14. The heptameric pore complex of claim 13 , wherein the polymerase is covalently linked to the alpha-hemolysin monomer.

15. The heptameric pore complex of claim 12 , wherein one or more of the alpha-hemolysin monomers further comprises a time-to-thread (TTT) substitution at a position corresponding to one or both of position 12 and position 17 of SEQ ID NO: 3.

16. The heptameric pore complex of claim 15 , wherein the TTT substitution or substitutions is/are selected from the group consisting of T12K, T12R, N17K, and N17R.

17. The heptameric pore complex of claim 12 , wherein each alpha-hemolysin monomer of the heptameric pore complex is disposed within a separate polypeptide from the other alpha-hemolysin monomers of the heptameric pore complex.

18. The heptameric pore complex of claim 12 , wherein from two to seven of the alpha-hemolysin monomers of the heptameric pore complex are disposed within a single polypeptide.

19. The isolated polypeptide of claim 12 , wherein at least one of the one or more alpha-hemolysin monomers further comprises an attachment component.

20. The isolated polypeptide of claim 19 , wherein the attachment component comprises a SpyTag or SpyCatcher peptide.

21. The isolated polypeptide of claim 19 , wherein the attachment component joins the alpha-hemolysin monomer to a DNA polymerase, an RNA polymerase, or a reverse transcriptase.

22. A method of making a heptameric pore complex, the method comprising heating a plurality of polypeptides of claim 3 in the presence of a lipid at a temperature greater than 25° C. for a sufficient period of time for the polypeptides to self-aggregate into alpha-hemolysin heptamers.

23. The method of claim 22 , wherein the temperature at which the polypeptides are heated is 30° C. or higher.

24. The method of claim 23 , wherein the temperature at which the polypeptides are heated is from 30° C. to 50° C.

25. A chip for nucleic acid sequencing, said chip comprising a heptameric pore complex of claim 12 disposed in a membrane adjacent to or in proximity to an electrode.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 26, 2020
From: CRAIG, TIMOTHY KELLOGG; CECH, CYNTHIA ANN; DORWART, MICHAEL; JENSEN, LIV ELISABETH; PORTER, MARSHALL WINSTON; TZITZILONIS, CHRISTOS; YANG, ALEXANDER HYUN-MIN
To: GENIA TECHNOLOGIES, INC.
Reel/Frame 051940/0621 →
MERGER AND CHANGE OF NAME Recorded Feb 26, 2020
From: GENIA TECHNOLOGIES, INC.; ROCHE SEQUENCING SOLUTIONS, INC.
To: ROCHE SEQUENCING SOLUTIONS, INC.
Reel/Frame 051940/0688 →
Continuity (4)
Continuation 15274770 · Sep 23, 2016
Provisional Application 62232175 · Sep 24, 2015
Provisional Application 62244852 · Oct 22, 2015
Related Publication 20190119745A1 · Apr 25, 2019